The
U.S. Preventive Services Task Force has added aromatase inhibitors to
its list of medications recommended to reduce breast cancer risk in
women at increased risk. This is a change from the group's 2013
recommendation on using drugs to lower breast cancer risk.
In the USPSTF's final recommendation statement in JAMA,
other recommendations are largely unchanged. Women aged 35 years and
older who are at increased risk for breast cancer can be offered
medications, also including tamoxifen and raloxifene, if they are at low
risk for side effects (grade B recommendation). Clinicians can use
widely available risk assessment tools or combinations of risk factors
(e.g., age 65 years or older with a first-degree relative with breast
cancer) to determine a patient's eligibility.
The task force continues to recommend against routinely using such medications in women who aren't at increased risk (grade D).
No comments:
Post a Comment